Why Farbe Firma is the Top Manufacturer of Succinylcholine Chloride Injection
- Maulik Sudani
- 9 hours ago
- 8 min read
Last Updated: June 25, 2026
TL;DR: Succinylcholine Chloride Injection — also known as suxamethonium chloride, a sterile aqueous solution of the only depolarising neuromuscular blocking agent in routine clinical use, supplied commonly as a 50 mg/mL solution (for example 100 mg in a 2 mL ampoule or 500 mg in a 10 mL vial) given intravenously — is the ultra-short-acting muscle relaxant anaesthetists rely on for rapid-sequence induction and tracheal intubation, where it produces fast, reliable paralysis within about a minute and wears off within minutes as it is broken down by plasma cholinesterase. Because the active is an ester that hydrolyses in water and the drug is given to anaesthetised patients whose airway depends on it, each ampoule or vial must deliver an exact, sterile, particulate-free dose at the labelled strength, with the stability-indicating assay, the related-substance (hydrolysis-degradant) profile, the tightly controlled acidic pH, validated cold-chain (2-8 degrees C) stability data, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Succinylcholine Chloride Injection at our Gujarat, India facility and supplies it to anaesthesia, emergency, critical-care and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Depolarising neuromuscular blocking agent - succinylcholine (suxamethonium) chloride binds the acetylcholine receptor at the neuromuscular junction and holds it open, producing rapid, profound, short-lived paralysis ideal for rapid-sequence intubation and brief procedures, and Succinylcholine Chloride Injection (50 mg/mL, intravenous) demands an exact, reproducible parenteral dose because the patient's airway depends on it.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated cold-chain compounding and ampoule and vial filling lines, control of the stability-indicating assay, the hydrolysis-related-substance profile, the tightly controlled acidic pH, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term, accelerated and validated cold-chain (2-8 degrees C) stability data, stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready cold-chain packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Succinylcholine Chloride Injection Demands a Premium Manufacturer
Succinylcholine Chloride Injection holds a critical, front-line place in operating theatres, emergency departments and intensive-care units across every market. It is the muscle relaxant an anaesthetist reaches for when a patient's airway must be secured in seconds rather than minutes - the rapid-sequence induction before emergency surgery, the difficult or full-stomach intubation where the lungs cannot be left unprotected, the laryngospasm or short procedure that needs deep relaxation and then an equally fast recovery. What makes succinylcholine, also known as suxamethonium, distinctive is its mechanism: it is the only depolarising neuromuscular blocker in routine use, acting like the body's own acetylcholine to bind the receptor at the neuromuscular junction and hold it open, so that after a brief flicker of fasciculations the muscle is paralysed within about a minute. It is then broken down quickly by plasma cholinesterase, which is why the block wears off within minutes - a profile no other relaxant matches. Because it is given to anaesthetised patients whose breathing has been deliberately stopped, the dose from each ampoule or vial must be exact, sterile, particulate-free and reliably the same from unit to unit, since the anaesthetist depends on a precise, ready, reproducible parenteral dose.
That clinical reality places real demands on the manufacturer. Succinylcholine Chloride Injection is an aqueous solution - typically 50 mg of suxamethonium chloride per millilitre, presented for example as 100 mg in a 2 mL ampoule or 500 mg in a 10 mL vial - so the assay must be exact and the fill volume accurate so that each unit delivers the labelled content. The active is a choline ester that slowly hydrolyses in water, so the solution is compounded at a tightly controlled, slightly acidic pH that holds that hydrolysis in check, and it must be kept under refrigeration: succinylcholine is a cold-chain product, stored at 2-8 degrees C, and the manufacturer must generate validated cold-chain stability data to support its shelf life and any permitted excursions. The solution must stay clear and colourless, free of visible and sub-visible particulates and low in endotoxin, and the manufacturer must run a stability-indicating method that resolves and quantifies succinylcholine and its hydrolysis degradants - succinylmonocholine, choline and succinic acid - without interference. The right sterilisation route - terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing - must be selected and validated, and the serious class cautions - the risk of malignant hyperthermia, of dangerous hyperkalaemia in susceptible patients, of bradycardia and of prolonged block in people with atypical or deficient plasma cholinesterase - clearly carried on the label. Choosing a Succinylcholine Chloride Injection manufacturer that treats the stability-indicating assay, hydrolysis-related-substance and pH control, validated cold-chain stability, fill-volume accuracy, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Succinylcholine Chloride Injection Manufacturer Apart
A world-class manufacturer of Succinylcholine Chloride Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of suxamethonium chloride with control of its hydrolysis-related substances by validated HPLC, which a hydrolytically labile ester used for airway management absolutely demands; a robust, validated sterilisation and fill process backed by a qualified cold chain that protects the labile active at its controlled acidic pH from compounding through to the point of use; and tender-ready dossier support, including cold-chain stability data, for a life-critical anaesthesia product procured through hospital-pharmacy and ministry-of-health channels. It starts with the active - pharmacopoeial-grade suxamethonium chloride sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay, the clarity and the pH of a hydrolytically sensitive solution. The bulk solution is compounded in water-for-injection at the tightly controlled, slightly acidic pH that keeps suxamethonium chloride stable, then sterile-filtered through 0.22 micron membrane and filled into ampoules or vials under ISO Class 5 conditions, with the validated sterilisation route locked in the master batch record and the cold chain maintained throughout. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of suxamethonium chloride by validated HPLC, the hydrolysis-related-substance profile, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intravenous administration. Because the active hydrolyses in water and the product is stored cold, assay accuracy, related-substance control, pH control and validated cold-chain stability are confirmed together so the assay and clarity stay within specification across shelf life.
Quality Systems Behind Every Succinylcholine Chloride Injection
Every Farbe Firma Succinylcholine Chloride Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of suxamethonium chloride against pharmacopoeial reference standards, control of its hydrolysis-related substances by HPLC, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule or vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated filling lines with 100 % inspection, qualified and temperature-monitored 2-8 degrees C cold rooms and cold-chain handling, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because succinylcholine is a hydrolytically labile, cold-chain depolarising blocker given parenterally and the assay, related-substance profile, pH and cold-chain stability drive both efficacy and safety, we treat the stability-indicating assay, the hydrolysis-related-substance profile, the controlled acidic pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both the labelled long-term cold-chain condition (5 degrees C) and an accelerated condition (25 degrees C / 60 % RH) per ICH Q1A, so the assay, clarity and pH stay within specification across the labelled refrigerated shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Succinylcholine Chloride Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad anaesthesia, emergency and critical-care small-volume parenteral portfolio. For Succinylcholine Chloride Injection specifically, we supply the 50 mg/mL solution in ampoule and vial presentations under WHO-GMP conditions, as a refrigerated cold-chain product, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the stability-indicating-assay, hydrolysis-related-substance, pH, cold-chain-stability, sterilisation and container-closure data package - ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A and validated cold-chain stability packages, stability-indicating method-validation data, sterilisation and container-closure reports, translated package inserts and artwork - including intravenous-only administration instructions, refrigerated-storage directions and the malignant-hyperthermia, hyperkalaemia and atypical-cholinesterase cautions - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate temperature-controlled shipping and logistics to the destination market. When a buyer needs Succinylcholine Chloride Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot, cold-chain plan and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through API sourcing, the development of a stability-indicating assay for a hydrolytically labile ester, hydrolysis-related-substance control, controlled-acidic-pH formulation design, cold-chain stability strategy, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a depolarising neuromuscular blocker where dose precision and potency directly govern airway safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Succinylcholine Chloride Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Succinylcholine Chloride Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated cold-chain compounding and ampoule and vial filling lines, qualified 2-8 degrees C cold storage, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Succinylcholine Chloride Injection do you supply?
Our standard presentation is the 50 mg/mL solution of suxamethonium (succinylcholine) chloride in an ampoule or vial (for example 100 mg in 2 mL or 500 mg in 10 mL), given intravenously and stored refrigerated at 2-8 degrees C. Custom strengths, fill configurations, ampoule and vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Succinylcholine Chloride Injection mainly used for?
Succinylcholine Chloride Injection is used to produce rapid, short-lasting muscle paralysis for tracheal intubation - especially rapid-sequence induction - and for brief procedures requiring deep relaxation. It is the only depolarising neuromuscular blocker in routine use and is broken down by plasma cholinesterase, so it acts within about a minute and recovers within minutes; Farbe Firma verifies the assay, hydrolysis-related-substance profile, pH, deliverable volume, particulate matter, endotoxin and cold-chain stability at release so each unit delivers a precise, reproducible dose. It is given intravenously by clinicians trained in airway management, and because of risks such as malignant hyperthermia and hyperkalaemia it is labelled accordingly.
Can Farbe Firma support country-specific registrations for Succinylcholine Chloride Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A and validated cold-chain stability packages, stability-indicating method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Succinylcholine Chloride Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, cold-chain handling, label complexity and dossier requirements. For our anaesthesia and emergency small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments